What Happened
The United States maintains that its economic restrictions against Iran are strictly designed to weaken the government’s financial access, disrupt oil exports, and limit funds for military programs and regional allies. Washington argues these steps are necessary to prevent the Iranian government from financing weapons programs, military operations, and armed groups across the Middle East.
However, broad curbs on a nation’s banks, shipping companies, energy sector, and foreign currency access trigger consequences that extend far beyond official decision-makers. Ordinary Iranians are facing rising prices, shortages, unemployment, and significant difficulties in obtaining imported medicines.
This reality has sparked intense debate over whether the strategy successfully pressures Tehran’s leadership or effectively penalizes millions of civilians. While Iranian officials, military leaders, and wealthy elites may retain greater access to resources and protected financial networks, lower-income families, pensioners, and people requiring medical treatment have far fewer options when prices rise or essential goods become scarce.
The Timeline
The American campaign against Tehran has continued to intensify throughout 2026. In August, the US Treasury announced another action targeting what it described as Iran’s clandestine shadow-banking network.
This move marked the eighth American action in 2026 specifically targeting financial networks allegedly used to move and repatriate Iranian revenue. Previous measures have focused on Iranian oil shipments, petrochemical sales, vessels, financial institutions, exchange houses, and companies accused of helping Tehran evade restrictions.
The Treasury Department has indicated it will continue to monitor these financial networks closely throughout the remainder of 2026, reviewing each new designation against the criteria for illicit activity and humanitarian impact. On paper, this framework means sanctions should not prevent ordinary Iranians from receiving medicine or other essential supplies, provided transactions do not involve particular sanctioned entities or prohibited activities.
Who Said What
American officials insist the sanctions are directed at state revenue streams and specific financial entities. The US Treasury’s Office of Foreign Assets Control states these goods can generally be sold to Iran, provided transactions do not involve particular sanctioned entities or prohibited activities.
However, the existence of a legal exemption does not guarantee a transaction will occur in practice. Banks, insurers, shipping companies, and pharmaceutical suppliers may decide that dealing with Iran carries too much legal or financial risk. This has led some institutions to avoid the Iranian market altogether through a practice described as over-compliance or de-risking.
When exemptions fail in practice, UN human-rights experts have repeatedly warned that over-compliance with US sanctions has harmed Iranian patients. Findings have highlighted difficulties accessing specialized medicines and treatments, including problems experienced by people with serious chronic illnesses.
While Iranian officials, military leaders, and wealthy elites may retain greater access to resources and protected financial networks, lower-income families, pensioners, and people requiring medical treatment have far fewer options when prices rise or essential goods become scarce. This dynamic does not remove responsibility from Iran’s government, as Tehran’s domestic policies, corruption, economic management, and spending priorities also influence population conditions.
Why This Matters
There has not been a definitive international court ruling declaring the entire US sanctions system against Iran to be unlawful collective punishment, meaning it would be inaccurate to present that conclusion as an established legal fact. However, critics argue broad economic sanctions can function like collective punishment in practice when predictable effects fall heavily on civilians rather than decision-makers.
Sanctions do not have to be abandoned entirely to reduce civilian harm, and more narrowly targeted measures could focus on named officials, military organizations, weapons procurement networks, and specific assets. At the same time, misconduct by the Iranian government does not erase the responsibility of sanctioning countries to monitor whether their policies cause disproportionate civilian suffering.
Suppliers face a choice: follow the letter of the law and risk legal repercussions, or refuse business entirely to ensure compliance. This creates a distinct gap between written policy and real-world consequences. The United States can accurately state that medicine is exempt while an Iranian patient remains unable to obtain it because the necessary financial system has become inaccessible.
The debate continues over whether the strategy successfully pressures Tehran’s leadership or effectively penalizes millions of civilians. As the campaign intensifies, the distinction between targeting a regime and punishing its population remains a central point of contention for policymakers and human rights observers alike.